Annotated catalogue of the Tachinidae (Insecta, Diptera) of the Afrotropical Region, with the description of seven new genera

The Tachinidae of the Afrotropical Region are catalogued and seven genera and eight species are newly described. There are 237 genera and 1126 species recognized, of which 101 genera and 1043 species are endemic to the region. The catalogue is based on examination of the primary literature comprising about 525 references as well as numerous name-bearing types and other specimens housed in collections. Taxa are arranged hierarchically and alphabetically under the categories of subfamily, tribe, genus, subgenus (where recognized), species, and rarely subspecies. Nomenclatural information is provided for all genusgroup and species-group names, including lists of synonyms (mostly restricted to Afrotropical taxa) and name-bearing type data. Species distributions are recorded by country within the Afrotropical Region and by larger geographical divisions outside the region. Additional information is given in the form of notes, numbering about 300 in the catalogue section. Seven genera and eight species are described as new: Afrophylax Cerretti & O’Hara with type species Sturmia aureiventris Villeneuve, 1910, gen. n. (Exoristinae, Eryciini); Austrosolieria Cerretti & O’Hara with type species Austrosolieria londti Cerretti & O’Hara, gen. n. and sp. n. (South Africa) and Austrosolieria freidbergi Cerretti & O’Hara, sp. n. (Malawi) (Tachininae, Leskiini); Carceliathrix Cerretti & O’Hara with type species Phorocera crassipalpis Villeneuve, 1938, gen. n. (Exoristinae, Eryciini); Filistea Cerretti & O’Hara with type species Viviania aureofasciata Curran, 1927, gen. n. and Filistea verbekei Cerretti & O’Hara, sp. n. (Cameroon, D.R. Congo, Uganda) (Exoristinae, Blondeliini); Mesnilotrix Cerretti & O’Hara with type species Dexiotrix empiformis Mesnil, 1976, gen. n. (Dexiinae, Dexiini); Myxophryxe Cerretti & O’Hara with type species Phorocera longirostris Villeneuve, 1938, gen. n., Myxophryxe murina Cerretti & O’Hara, sp. n. (South Africa), Myxophryxe regalis Cerretti & O’Hara, sp. n. (South Africa), and Myxophryxe satanas Cerretti & O’Hara, sp. n. (South Africa) (Exoristinae, Goniini); and Stiremania Cerretti & O’Hara with type species Stiremania karoo Cerretti & O’Hara, gen. n. and sp. n. (South Africa), and Stiremania robusta Cerretti & O’Hara, sp. n. (South Africa) (Exoristinae, Goniini). Paraclara Bezzi, 1908 is transferred from the Cylindromyiini to the Hermyini, comb. n. Sarrorhina Villeneuve, 1936 is transferred from the Minthoini to the Graphogastrini, comb. n. Three genera are newly recorded from the Afrotropical Region: Madremyia Townsend, 1916 (Eryciini); Paratrixa Brauer & Bergenstamm, 1891 (Blondeliini); and Simoma Aldrich, 1926 (Goniini). Three genera previously recorded from the Afrotropical Region are no longer recognized from the region: Calozenillia Townsend, 1927 (Palaearctic, Oriental and Australasian regions); Eurysthaea Robineau-Desvoidy, 1863 (Palaearctic, Oriental and Australasian regions); and Trixa Meigen, 1824 (Palaearctic and Oriental regions). Two species are newly recorded from the Afrotropical Region: Amnonia carmelitana Kugler, 1971 (Ethiopia, Kenya); and Simoma grahami Aldrich, 1926 (Namibia). Three species previously recorded from the Afrotropical Region are no longer recognized from the region: Euthera peringueyi Bezzi, 1925 (Oriental Region); Hamaxia incongrua Walker, 1860 (Palaearctic, Oriental and Australasian regions); Leucostoma tetraptera (Meigen, 1824) (Palaearctic Region). New replacement names are proposed for five preoccupied names of Afrotropical species: Billaea rubida O’Hara & Cerretti for Phorostoma rutilans Villeneuve, 1916, preoccupied in the genus Billaea Robineau-Desvoidy, 1830 by Musca rutilans Fabricius, 1781, nom. n.; Cylindromyia braueri O’Hara & Cerretti for Ocyptera nigra Villeneuve, 1918, preoccupied in the genus Cylindromyia Meigen, 1803 by Glossidionophora nigra Bigot, 1885, nom. n.; Cylindromyia rufohumera O’Hara & Cerretti for Ocyptera scapularis Villeneuve, 1944, preoccupied in the genus Cylindromyia Meigen, 1803 by Ocyptera scapularis Loew, 1845, nom. n.; Phytomyptera longiarista O’Hara & Cerretti for Phytomyzoneura aristalis Villeneuve, 1936, preoccupied in the genus Phytomyptera Rondani, 1845 by Phasiostoma aristalis Townsend, 1915, nom. n.; and Siphona (Siphona) pretoriana O’Hara & Cerretti for Siphona laticornis Curran, 1941, preoccupied in the genus Siphona Meigen, 1803 by Actia laticornis Malloch, 1930, nom. n. New type species fixations are made under the provisions of Article 70.3.2 of the ICZN Code for two genus-group names: Lydellina Villeneuve, 1916, type species newly fixed as Lydellina villeneuvei Townsend, 1933 (valid genus name); and Sericophoromyia Austen, 1909, type species newly fixed as Tachina quadrata Wiedemann, 1830 (synonym of Winthemia Robineau-Desvoidy, 1830). Lectotypes are designated for the following nine nominal species based on examination of one or more syntypes of each: Degeeria crocea Villeneuve, 1950; Degeeria semirufa Villeneuve, 1950; Erycia brunnescens Villeneuve, 1934; Exorista oculata Villeneuve, 1910; Kiniatilla tricincta Villeneuve, 1938; Myxarchiclops caffer Villeneuve, 1916; Ocyptera linearis Villeneuve, 1936; Peristasisea luteola Villeneuve, 1934; and Phorocera crassipalpis Villeneuve, 1938. The following four genus-group names that were previously treated as junior synonyms or subgenera are recognized as valid generic names: Bogosiella Villeneuve, 1923, status revived; Dyshypostena Villeneuve, 1939, status revived; Perlucidina Mesnil, 1952, status revived; and Thelymyiops Mesnil, 1950, status n. The following six species-group names that were previously treated as junior synonyms are recognized as valid species names: Besseria fossulata Bezzi, 1908, status revived; Degeeria cinctella Villeneuve, 1950, status revived (as Medina cinctella (Villeneuve)); Nemoraea miranda intacta Villeneuve, 1916, status revived (as Nemoraea intacta Villeneuve); Succingulum exiguum Villeneuve, 1935, status revived (as Trigonospila exigua (Villeneuve)); Wagneria rufitibia abbreviata Mesnil, 1950, status n. (as Periscepsia abbreviata (Mesnil)); and Wagneria rufitibia nudinerva Mesnil, 1950, status n. (as Periscepsia nudinerva (Mesnil)). The following 25 new or revived combinations are proposed: Afrophylax aureiventris (Villeneuve, 1910), comb. n.; Blepharella orbitalis (Curran, 1927), comb. n.; Bogosiella pomeroyi Villeneuve, 1923, comb. revived; Brachychaetoides violacea (Curran, 1927), comb. n.; Carceliathrix crassipalpis (Villeneuve, 1938), comb. n.; Charitella whitmorei (Cerretti, 2012), comb. n.; Dyshypostena edwardsi (van Emden, 1960), comb. n.; Dyshypostena tarsalis Villeneuve, 1939, comb. revived; Estheria buccata (van Emden, 1947), comb. n.; Estheria surda (Curran, 1933), comb. n.; Filistea aureofasciata (Curran, 1927), comb. n.; Madremyia setinervis (Mesnil, 1968), comb. n.; Mesnilotrix empiformis (Mesnil, 1976), comb. n.; Myxophryxe longirostris (Villeneuve, 1938), comb. n.; Nealsomyia chloronitens (Mesnil, 1977), comb. n.; Nealsomyia clausa (Curran, 1940), comb. n.; Nilea longicauda (Mesnil, 1970), comb. n.; Paratrixa aethiopica Mesnil, 1952, comb. revived; Paratrixa stammeri Mesnil, 1952, comb. revived; Perlucidina africana (Jaennicke, 1867), comb. n.; Perlucidina perlucida (Karsch, 1886), comb. revived; Prolophosia retroflexa (Villeneuve, 1944), comb. n.; Sturmia profana (Karsch, 1888), comb. n.; additionally, Ceromasia rufiventris Curran, 1927 is treated as an unplaced species of Goniini, comb. n. and Hemiwinthemia stuckenbergi Verbeke, 1973 is treated as an unplaced species of Leskiini, comb. n. New or revived generic and specific synonymies are proposed for the following nine names: Afrosturmia Curran, 1927 with Blepharella Macquart, 1851, syn. n.; Archiphania van Emden, 1945 with Catharosia Rondani, 1868, syn. revived; Besseria longicornis Zeegers, 2007 with Besseria fossulata Bezzi, 1908 (current name Besseria fossulata), syn. n.; Dexiomera Curran, 1933 with Estheria Robineau-Desvoidy, 1830, syn. n.; Hemiwinthemia francoisi Verbeke, 1973 with Nemoraea capensis Schiner, 1868 (current name Smidtia capensis), syn. n.; Kinangopana van Emden, 1960 with Dyshypostena Villeneuve, 1939, syn. n.; Metadrinomyia Shima, 1980 with Charitella Mesnil, 1957, syn. n.; Phorocera majestica Curran, 1940 with Phorocera longirostris Villeneuve, 1938 (current name Myxophryxe longirostris), syn. n.; and Podomyia discalis Curran, 1939 with Antistasea fimbriata Bischof, 1904 (current name Antistasea fimbriata), syn. n

Structural elaboration of the surprising ortho-zincation of benzyl methyl ether

Breaking with convention, the reaction of the sodium zincate, [(TMEDA)Na(μ-TMP)(μ-tBu)Zn(tBu)] with benzyl methyl ether (PhCH2OMe) produces exclusively an ortho-zincated intermediate [(TMEDA)Na(μ-TMP)(μ-C6H4CH2OMe)Zn(tBu)] instead of the expected 'thermodynamic' α-metallated product

Use of proton pump inhibitors to treat persistent throat symptoms: Multicentre, double blind, randomised, placebo controlled trial

Objective. To assess the use of proton pump inhibitors (PPIs) to treat persistent throat symptoms. Design. Pragmatic, double blind, placebo controlled, randomised trial. Setting. Eight ear, nose, and throat outpatient clinics, United Kingdom. Participants. 346 patients aged 18 years or older with persistent throat symptoms who were randomised according to recruiting centre and baseline severity of symptoms (mild or severe): 172 to lansoprazole and 174 to placebo. Intervention. Random blinded allocation (1:1) to either 30 mg lansoprazole twice daily or matched placebo twice daily for 16 weeks. Main outcome measures. Primary outcome was symptomatic response at 16 weeks measured using the total reflux symptom index (RSI) score. Secondary outcomes included symptom response at 12 months, quality of life, and throat appearances. Results. Of 1427 patients initially screened for eligibility, 346 were recruited. The mean age of the study sample was 52.2 (SD 13.7) years, 196 (57%) were women, and 162 (47%) had severe symptoms at presentation; these characteristics were balanced across treatment arms. The primary analysis was performed on 220 patients who completed the primary outcome measure within a window of 14-20 weeks. Mean RSI scores were similar between treatment arms at baseline: lansoprazole 22.0 (95% confidence interval 20.4 to 23.6) and placebo 21.7 (20.5 to 23.0). Improvements (reduction in RSI score) were observed in both groups—score at 16 weeks: lansoprazole 17.4 (15.5 to19.4) and placebo 15.6 (13.8 to 17.3). No statistically significant difference was found between the treatment arms: estimated difference 1.9 points (95% confidence interval −0.3 to 4.2 points; P=0.096) adjusted for site and baseline symptom severity. Lansoprazole showed no benefits over placebo for any secondary outcome measure, including RSI scores at 12 months: lansoprazole 16.0 (13.6 to 18.4) and placebo 13.6 (11.7 to 15.5): estimated difference 2.4 points (−0.6 to 5.4 points). Conclusions. No evidence was found of benefit from PPI treatment in patients with persistent throat symptoms. RSI scores were similar between the lansoprazole and placebo groups after 16 weeks of treatment and at the 12 month follow-up

Trading Patterns and Market Integration in Overlapping Experimental Asset Markets

This paper examines trading patterns and market integration using laboratory asset markets. Our markets are designed to approximately correspond to the trading day for stocks cross-listed in markets in Europe and North America. Some of our markets feature timing restrictions so that participants cannot trade across markets except during a fully integrated overlap period. Comparison of markets with and without timing restrictions shows that restrictions reduce trading activity and shift transactions to the overlap period. When asset values are extreme, price discovery can be impeded when trading restrictions exist. The measurement of liquidity suggests that trading restrictions increase overall spreads

The nature and content of rumination for head and neck cancer survivors

IntroductionHead and neck cancer (HNC) diagnosis and treatment can be a significant life trauma. Some HNC survivors experience post-traumatic growth (PTG), which has been linked with better health-related quality-of-life. Empirical research on PTG, and theoretical models, point to the importance of being able to purposely make sense of the traumatic experience. Intrusive rumination, by contrast, is linked to poorer outcomes. This study explored HNC survivors’ experiences of rumination.MethodsTwenty HNC survivors between 9 months and 5 years post-diagnosis were recruited (11 male, 9 female, age range 46–83). They had a range of HNC sub-types and cancer treatments. Participants underwent a semi-structured interview about their cancer diagnosis and treatment. Reflexive thematic analysis identified themes and sub-themes around rumination.ResultsFour themes with linked subthemes on the content and process of rumination were identified. Theme 1 was rumination and worry related to diagnosis. Here, survivors discussed how the HNC diagnosis and plans for treatment had dominated their initial thoughts. Theme 2 was processing the trauma of HNC. This theme reflected rumination on the traumatic experience of diagnosis and treatment and how the participant was reacting to it. Theme 3 was considering the impact. This theme encompassed retrospective thinking (e.g., on treatment decisions made) and comparisons between the participant now versus the early days after diagnosis. Theme 4 was continued rumination. This theme included ongoing intrusive and distressing rumination about the trauma and impact of cancer. Those who expressed ongoing rumination revisited fears (e.g., concerns about their future) or returned to negative experiences (e.g., distressing exchanges with healthcare professionals or what they perceived as poor care).ConclusionThis study uniquely describes the nature and content of rumination following HNC. Early intrusive rumination is common and may reflect perceptions of cancer as an existential threat. Over time, rumination can become more reflective and move towards deliberate meaning-making. Some HNC survivors may benefit from interventions to reduce barriers to this transition. The content of distressing and difficult to control rumination (commonly focused on ongoing fears or inability to resolve difficult experiences) helps to identify those who may benefit from more directed psychological support.</jats:sec

Hyperbaric oxygen treatment in autism spectrum disorders

Traditionally, hyperbaric oxygen treatment (HBOT) is indicated in several clinical disorders include decompression sickness, healing of problem wounds and arterial gas embolism. However, some investigators have used HBOT to treat individuals with autism spectrum disorders (ASD). A number of individuals with ASD possess certain physiological abnormalities that HBOT might ameliorate, including cerebral hypoperfusion, inflammation, mitochondrial dysfunction and oxidative stress. Studies of children with ASD have found positive changes in physiology and/or behavior from HBOT. For example, several studies have reported that HBOT improved cerebral perfusion, decreased markers of inflammation and did not worsen oxidative stress markers in children with ASD. Most studies of HBOT in children with ASD examined changes in behaviors and reported improvements in several behavioral domains although many of these studies were not controlled. Although the two trials employing a control group reported conflicting results, a recent systematic review noted several important distinctions between these trials. In the reviewed studies, HBOT had minimal adverse effects and was well tolerated. Studies which used a higher frequency of HBOT sessions (e.g., 10 sessions per week as opposed to 5 sessions per week) generally reported more significant improvements. Many of the studies had limitations which may have contributed to inconsistent findings across studies, including the use of many different standardized and non-standardized instruments, making it difficult to directly compare the results of studies or to know if there are specific areas of behavior in which HBOT is most effective. The variability in results between studies could also have been due to certain subgroups of children with ASD responding differently to HBOT. Most of the reviewed studies relied on changes in behavioral measurements, which may lag behind physiological changes. Additional studies enrolling children with ASD who have certain physiological abnormalities (such as inflammation, cerebral hypoperfusion, and mitochondrial dysfunction) and which measure changes in these physiological parameters would be helpful in further defining the effects of HBOT in ASD

Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation, and Oxidative Stress

AbstractBackgroundRecent trials of fish oil for the prevention of atrial fibrillation (AF) recurrence have provided mixed results. Notable uncertainties in the existing evidence base include the roles of high-dose fish oil, inflammation, and oxidative stress in patients with paroxysmal or persistent AF not receiving conventional antiarrhythmic (AA) therapy.ObjectivesThe aim of this study was to evaluate the influence of high-dose fish oil on AF recurrence, inflammation, and oxidative stress parameters.MethodsWe performed a double-blind, randomized, placebo-controlled, parallel-arm study in 337 patients with symptomatic paroxysmal or persistent AF within 6 months of enrollment. Patients were randomized to fish oil (4 g/day) or placebo and followed, on average, for 271 ± 129 days.ResultsThe primary endpoint was time to first symptomatic or asymptomatic AF recurrence lasting >30 s. Secondary endpoints were high-sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO). The primary endpoint occurred in 64.1% of patients in the fish oil arm and 63.2% of patients in the placebo arm (hazard ratio: 1.10; 95% confidence interval: 0.84 to 1.45; p = 0.48). hs-CRP and MPO were within normal limits at baseline and decreased to a similar degree at 6 months (Δhs-CRP, 11% vs. −11%; ΔMPO, −5% vs. −9% for fish oil vs. placebo, respectively; p value for interaction = NS).ConclusionsHigh-dose fish oil does not reduce AF recurrence in patients with a history of AF not receiving conventional AA therapy. Furthermore, fish oil does not reduce inflammation or oxidative stress markers in this population, which may explain its lack of efficacy. (Multi-center Study to Evaluate the Effect of N-3 Fatty Acids [OMEGA-3] on Arrhythmia Recurrence in Atrial Fibrillation [AFFORD]; NCT01235130)

Understanding variation in ambulance service non-conveyance rates: a mixed methods study

Background In England in 2015/16, ambulance services responded to nearly 11 million calls. Ambulance Quality Indicators show that half of the patients receiving a response by telephone or face to face were not conveyed to an emergency department. A total of 11% of patients received telephone advice only. A total of 38% of patients were sent an ambulance but were not conveyed to an emergency department. For the 10 large ambulance services in England, rates of calls ending in telephone advice varied between 5% and 17%. Rates of patients who were sent an ambulance but not conveyed to an emergency department varied between 23% and 51%. Overall non-conveyance rates varied between 40% and 68%. Objective To explain variation in non-conveyance rates between ambulance services. Design A sequential mixed methods study with five work packages. Setting Ten of the 11 ambulance services serving > 99% of the population of England. Methods (1) A qualitative interview study of managers and paramedics from each ambulance service, as well as ambulance commissioners (totalling 49 interviews undertaken in 2015). (2) An analysis of 1 month of routine data from each ambulance service (November 2014). (3) A qualitative study in three ambulance services with different published rates of calls ending in telephone advice (120 hours of observation and 20 interviews undertaken in 2016). (4) An analysis of routine data from one ambulance service linked to emergency department attendance, hospital admission and mortality data (6 months of 2013). (5) A substudy of non-conveyance for people calling 999 with breathing problems. Results Interviewees in the qualitative study identified factors that they perceived to affect non-conveyance rates. Where possible, these perceptions were tested using routine data. Some variation in non-conveyance rates between ambulance services was likely to be due to differences in the way rates were calculated by individual services, particularly in relation to telephone advice. Rates for the number of patients sent an ambulance but not conveyed to an emergency department were associated with patient-level factors: age, sex, deprivation, time of call, reason for call, urgency level and skill level of attending crew. However, variation between ambulance services remained after adjustment for patient-level factors. Variation was explained by ambulance service-level factors after adjustment for patient-level factors: the percentage of calls attended by advanced paramedics [odds ratio 1.05, 95% confidence interval (CI) 1.04 to 1.07], the perception of ambulance service staff and commissioners that advanced paramedics were established and valued within the workforce of an ambulance service (odds ratio 1.84, 95% CI 1.45 to 2.33), and the perception of ambulance service staff and commissioners that senior management was risk averse regarding non-conveyance within an ambulance service (odds ratio 0.78, 95% CI 0.63 to 0.98). Limitations Routine data from ambulance services are complex and not consistently collected or analysed by ambulance services, thus limiting the utility of comparative analyses. Conclusions Variation in non-conveyance rates between ambulance services in England could be reduced by addressing variation in the types of paramedics attending calls, variation in how advanced paramedics are used and variation in perceptions of the risk associated with non-conveyance within ambulance service management. Linking routine ambulance data with emergency department attendance, hospital admission and mortality data for all ambulance services in the UK would allow comparison of the safety and appropriateness of their different non-conveyance rates. Funding The National Institute for Health Research Health Services and Delivery Research programme

A randomised, placebo controlled trial of extra-oesophageal reflux treatment in the management of upper respiratory symptoms [TOPPITS:Trial of Proton Pump Inhibitors in Throat Symptoms]

Background. Persistent throat symptoms, such as throat clearing, globus sensation, voice change and catarrh are extremely common. On very limited evidence, they are increasingly attributed to “laryngopharyngeal reflux (LPR)” and treated with proton pump inhibitors (PPIs) in primary and secondary care. Methods. A double blind placebo controlled UK multicentre phase III trial randomly allocated adults with persistent throat symptoms 1:1 to either 30 mg of Lansoprazole or matched placebo twice daily for 16 weeks, stratified by centre and symptom severity. The primary outcome was patient-reported symptomatic response, measured by the total Reflux Symptom Index (RSI) score at the end of therapy. Secondary outcomes included safety, further symptoms and quality of life measures at 12-months. Results. 346 participants were randomised from 8 UK centres: mean (sd) age 52 (13), 196 (57%) female, 162 (47%) severe symptoms, balanced across randomised groups. Mean RSI scores (95% CI) were similar at baseline- Lansoprazole: 22.0 (20.4, 23.6), placebo: 21.7 (20.5, 23.0). Improvements (reduction in score) were observed in both groups at 16-weeks: Lansoprazole: 17.4 (15.5, 19.4), placebo: 15.6 (13.8, 17.3) (p=0.096 adjusted by site, severity). There was no statistically significant difference between randomised groups. No significant differences were observed in the secondary outcome measures. Conclusions. TOPPITS is the largest, definitive trial to assess PPI effectiveness for persistent throat symptoms. It found no advantage of Lansoprazole over placebo in a range of outcomes. The near routine use of PPIs for throat symptoms should be discontinued